Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBT Margin (2021 - 2025)

Historic EBT Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 102.91%.

  • Rhythm Pharmaceuticals' EBT Margin rose 293700.0% to 102.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 110.07%, marking a year-over-year increase of 1194500.0%. This contributed to the annual value of 200.0% for FY2024, which is 377800.0% up from last year.
  • Rhythm Pharmaceuticals' EBT Margin amounted to 102.91% in Q3 2025, which was up 293700.0% from 95.45% recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' EBT Margin registered a high of 187874.29% during Q1 2021, and its lowest value of 14748.54% during Q2 2021.
  • For the 5-year period, Rhythm Pharmaceuticals' EBT Margin averaged around 8331.39%, with its median value being 242.98% (2023).
  • The largest annual percentage gain for Rhythm Pharmaceuticals' EBT Margin in the last 5 years was 142536400bps (2022), contrasted with its biggest fall of -1913810300bps (2022).
  • Rhythm Pharmaceuticals' EBT Margin (Quarter) stood at 2798.84% in 2021, then surged by 83bps to 483.42% in 2022, then surged by 65bps to 170.99% in 2023, then skyrocketed by 39bps to 103.71% in 2024, then increased by 1bps to 102.91% in 2025.
  • Its EBT Margin was 102.91% in Q3 2025, compared to 95.45% in Q2 2025 and 151.11% in Q1 2025.